木麻黄鞣亭 | 82262-94-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 单宁
• 中文名称: 木麻黄鞣亭
• 英文名称: 1-O-Galloylpedunculagin
• 英文别名: (7,8,9,12,13,14,28,29,30,33,34,35-dodecahydroxy-4,17,25,38-tetraoxo-3,18,21,24,39-pentaoxaheptacyclo[20.17.0.02,19.05,10.011,16.026,31.032,37]nonatriaconta-5,7,9,11,13,15,26,28,30,32,34,36-dodecaen-20-yl) 3,4,5-trihydroxybenzoate
• CAS: 82262-94-0；79786-00-8
• 化学式: C₄₁H₂₈O₂₆
• 分子量: 936.6
• InChiKey: SWRFKGRMQVLMKA-UHFFFAOYSA-N

物化性质

• 沸点：
  1662.7±65.0 °C(Predicted)
• 密度：
  2.23±0.1 g/cm3(Predicted)
• LogP：
  4.700 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  67
• 可旋转键数：
  3
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  444
• 氢给体数：
  15
• 氢受体数：
  26

文献信息

• [EN] GLUCOSE SENSITIVE PHENYLBORATE ACID CAPSULES FOR INSULIN DELIVERY<br/>[FR] CAPSULES D'ACIDE PHENYLBORATE SENSIBLES AU GLUCOSE POUR L'ADMINISTRATION D'INSULINE
  申请人：UNIV MELBOURNE

  公开号：WO2016191816A1

  公开（公告）日：2016-12-08

  The present invention relates to capsules, and the method for making such capsules, having a boronate linked organic network layer comprising (a) a plurality of boronic acid containing moieties and (b) a plurality of galloyi linking moieties, which capsules are responsive to externally applied stimuli, for applications including cell encapsulation, advanced drug delivery, biomedical diagnostics, micro-reactions, and the formation of biomimetic protocells.

  本发明涉及胶囊及制造此类胶囊的方法，其具有硼酸酯键连的有机网络层，包括(a) 多种含硼酸基团的基元和(b) 多种没食子酸连接基元，这些胶囊对外界应用的刺激具有响应性，适用于细胞封装、先进药物传递、生物医学诊断、微反应和仿生原细胞的形成等应用。
• Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders
  申请人：Amazentis SA

  公开号：US20170143667A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供了一些化合物或化合物前体的组合物，可用于各种治疗应用，包括治疗和/或预防与线粒体活性降低或不足有关的疾病或障碍，包括衰老或压力、糖尿病、肥胖症和神经退行性疾病等。这些化合物通常与石榴酸单宁和尿石榴素A等尿石榴素有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可以在通常健康的个体中有益地用于增加或维持代谢率，减少体脂百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。
• COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS
  申请人：Amazentis SA

  公开号：US20170143666A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a. variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and uroiithin A. In certain embodiment the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供的是包含化合物或其前体的组合物，可用于各种治疗应用，包括但不限于治疗与线粒体活性降低或不足有关的疾病或紊乱，如衰老或压力、糖尿病、肥胖症和神经退行性疾病。这些化合物通常与石榴酸单宁和尿石榴素A有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可用于一般健康的人，以增加或维持代谢率，降低身体脂肪百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。
• Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof
  申请人：Amazentis SA

  公开号：US20140018415A1

  公开（公告）日：2014-01-16

  Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

  本发明涉及用于增加自噬和促进寿命的方法、化合物和组合物。所述方法、化合物和组合物涉及urolithins和urolithin前体及其使用。某些urolithins由公式I表示，而某些urolithin前体由公式IV表示。所述urolithin可以是urolithin A、urolithin B、urolithin C或urolithin D。所述urolithin前体可以是鞣花酸或鞣花酸单宁。所述方法包括化合物和组合物的体内、体外和体外使用。
• Antiviral agent
  申请人：Julphar Pharma GmbH

  公开号：EP0896792A1

  公开（公告）日：1999-02-17

  The present invention relates to novel compositions having antiviral and antitumor activity. Further, the invention relates to methods for controlling viruses and for selectively degrading viral nucleic acids.

  本发明涉及具有抗病毒和抗肿瘤活性的新型组合物。此外，本发明还涉及控制病毒和选择性降解病毒核酸的方法。